> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# FDA Flags Misleading Promotion of Generic Ketamine Drug
- URL: https://www.fdaweb.com/fda-flags-misleading-promotion-of-generic-ketamine-drug/
- Published: 2025-11-24T12:00:00.000Z
- Updated: 2026-09-14T15:27:38.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5160275

FDA has cited PharmaTher over alleged misleading promotional claims for its generic ketamine. An agency review found the company’s Web page omitted required risk information about the drug product. It also claimed the generic ketamine was approved “for surgical pain management” or “pain and surgery management,” language that deviates from the actual approved indication of the reference listed drug Ketalar Injection and misrepresents the drug’s use, according to a just-posted [untitled letter](https://www.fda.gov/media/189734/download?attachment&ref=fdaweb.com).

The letter told the company to immediately cease and desist all misleading promotional communications for the product. It was also instructed to submit a written response detailing all promotional materials for the drug, the date they were submitted (if at all) under Form FDA-2253, and a plan to discontinue or modify the communications.